Molecular and Clinical Advances in Anticancer Drug Resistance

1. Front Matter

   Pages i-xii

   PDF

2. New mechanisms of gene amplification in drug resistance (the episome model)

   • Daniel D. Von Hoff

   Pages 1-11

3. DNA-damage inducible genes

   • Matilda A. Papathanasiou, Albert J. Fornace Jr.

   Pages 13-36

4. Molecular biology of P-glycoprotein

   • Marilyn M. Cornwell

   Pages 37-56

5. Resistance to inhibitors of DNA topoisomerases

   • Daniel M. Sullivan, Warren E. Ross

   Pages 57-99

6. Expression of the MDR1 gene in human cancers

   • Lori J. Goldstein, Michael M. Gottesman, Ira Pastan

   Pages 101-119

7. Immunoblot detection of P-glycoprotein in human tumors and cell lines

   • William J. Fredericks, YanFeng Chen, Raymond M. Baker

   Pages 121-149

8. Modulators of P-glycoprotein-associated multidrug resistance

   • William T. Beck

   Pages 151-170

9. Clinical implications of multidrug resistance to chemotherapy

   • E. G. E. de Vries, H. M. Pinedo

   Pages 171-186

10. The role of P-glycoprotein in drug-resistant hematologic malignancies

    • William S. Dalton, Thomas M. Grogan, Thomas P. Miller

    Pages 187-208

11. DNA repair in drug resistance: Studies on the repair process at the level of the gene

    • Charles J. Link Jr., Vilhelm A. Bohr

    Pages 209-232

12. Mechanisms of resistance to cisplatin

    • Alan Eastman

    Pages 233-249

13. The role of metallothioneins in anticancer drug resistance

    • Robert R. Bahnson, Alakananda Basu, John S. Lazo

    Pages 251-260

14. Modulation of antitumor alkylating agents (AA)

    • Beverly A. Teicher, Emil Frei III

    Pages 261-295

15. Back Matter

    Pages 297-308

    PDF

The importance of drug resistance in cancer chemotherapy cannot be over­ stated. The 500,000 patients who die every year from cancer in the United States have, in most cases, been treated with chemotherapy. Many of these patients responded initially to chemotherapy, but death resulted from the development of drug-resistant tumors. In the first volume in the series. Drug Resistance in Chemotherapy the results of comprehensive laboratory studies aimed at understanding the mechanisms for resistance to individual agents and to the development of broad cross-resistance were described. In the past 2 years there has been substantial progress in understanding the molecular biology associated with these mechanisms of drug resistance. For the first time we are starting to understand which mechanisms are playing an im­ portant role in human tumors, and even more importantly, clinical trials have recently been initiated in an effort to reverse specific forms of drug resistance. The purpose of this volume is to describe the new advances, both at the molecular level and in the clinic regarding mechanisms of drug resistance and potential ways this resistance can be circumvented. This volume is focused upon mechanisms of resistance associated with two major classes of anticancer drugs: alkylating agents (including cisplatin) and the natural products (e. g. , adriamycin and vinblastine). The first section of the book describes new insights into the genetic mechanisms associated with drug resistance.

• DNA
• cancer
• cell
• chemotherapy
• clinical trial
• drug
• drug resistance
• molecular biology
• research
• resistance

' This book contains much valuable information, including an extensive bibliography. As such, it is primarily of value as a reference text both for clinical and basic scientific research staff. ' Journal of the National Cancer Institute 84:22 1992
'This book would be a helpful text for basic researchers, clinical investigators, and medical housestaff. It is well written and can be read in a relatively short period of time.' Breast Cancer Research and Treatment 19 1991

• Fox Chase Cancer Center, USA

  Robert F. Ozols

Policies and ethics